Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceutical Policy topic
No spam. Unsubscribe anytime.
Senate hears bill to expand Medicaid coverage for GLP-1 medications for obesity with clinical safeguards
Summary
Sponsor proposed adding GLP-1 drugs to Medicaid coverage for patients meeting BMI and comorbidity criteria to treat obesity as chronic disease; Medicaid officials said many GLP-1 uses are already covered for diabetes and for BMI with comorbidities, and that a revised fiscal note will be needed for any coverage change.
Sen. Sue Prentiss introduced legislation to expand Medicaid coverage for GLP-1 agonist medications used to treat obesity when patients meet specified BMI thresholds and comorbidity criteria. The sponsor framed obesity as a chronic disease and argued that treating it earlier with evidence-based medication could prevent costly downstream conditions such as diabetes complications, dialysis, amputations and cardiovascular events.
Medicaid staff said DHHS already covers GLP-1 medications for type 2 diabetes and for adults with BMI >=27 who have at least one weight-related comorbidity (for example, obstructive sleep apnea or cardiovascular risk conditions) under existing prior-authorization criteria. Peg Clifford, Medicaid's pharmacy director, noted that the department currently excludes prescriptions written "solely for weight loss" outside of EPSDT for children. She said the agency would need to run a fiscal estimate if the committee adopts the sponsor's amendment.
Clinicians and primary care physicians testified in support, offering patient examples of meaningful weight loss and clinical benefit when medication was combined with behavioral support. Providers and insurers discussed alternative, lower-cost pharmacologic options (such as older generic appetite-suppressant combinations) and the need for clinical monitoring and behavioral programs alongside medication.
Committee members requested a revised fiscal note and technical conversation with DHHS before advancing any coverage mandate to Medicaid or the commercial market.
